Hypertrophic cardiomyopathy (HCM) is the most common heart disease of domestic cats, affecting an estimated 15% of the general feline population and up to 26% of cats over the age of 9. Despite this prevalence, it is frequently called the ‘silent killer’ because it often produces no clinical signs whatsoever until a sudden and catastrophic event — acute congestive heart failure, arterial thromboembolism, or sudden cardiac death — signals its presence for the first time.

This article explains what HCM is, which cats are at highest risk, how it is diagnosed, what treatment can and cannot achieve, and how owners can monitor and support a cat living with this condition.

What Is Hypertrophic Cardiomyopathy?

HCM is defined by pathological hypertrophy (thickening) of the left ventricular myocardium — the muscular wall of the heart’s main pumping chamber — in the absence of any other disease that could cause the same structural change (such as systemic hypertension or hyperthyroidism). As the ventricular walls thicken, the chamber becomes smaller and stiffer, impairing its ability to relax and fill with blood during diastole. This diastolic dysfunction is the primary haemodynamic problem in HCM.

Over time, the combination of impaired filling, elevated filling pressures, and structural remodelling can lead to several serious complications: left atrial enlargement (stretching the chamber that receives blood from the lungs), pulmonary oedema (fluid accumulation in the lungs), pleural effusion (fluid around the lungs), and the formation of intracardiac thrombi that can break off and lodge in major arteries.

Diastolic vs. Systolic Dysfunction Most feline heart disease, including HCM, affects diastolic function — the heart’s ability to relax and fill. This is different from systolic dysfunction (reduced pumping ability), which is more common in human heart failure. The distinction matters because some human heart failure medications are inappropriate or harmful in cats with diastolic dysfunction.

Which Cats Are at Risk?

HCM can affect any cat of any age or breed, but several risk factors are well established:

Breed Predispositions

Genetic mutations in sarcomeric proteins — the contractile proteins that make up cardiac muscle — have been identified in two breeds and confer significantly elevated risk:

• Maine Coon: A mutation in the MYBPC3 gene (myosin-binding protein C) is found in approximately 35% of Maine Coons. Cats carrying two copies of the mutation (homozygous) develop more severe disease at a younger age than heterozygous carriers.
• Ragdoll: A different MYBPC3 mutation has been identified in Ragdolls, with a prevalence of approximately 30%. The clinical course in Ragdolls tends to be somewhat less severe than in Maine Coons.

Other breeds with elevated HCM prevalence include Persian, British Shorthair, Norwegian Forest Cat, Sphynx, and Birman, though specific causative mutations have not been identified for all. Domestic shorthair cats — the most common cat type overall — also develop HCM, making breed alone an insufficient risk assessment.

Age and Sex

HCM can occur at any age, from under one year (particularly in genetically predisposed breeds) to over 15 years. Male cats are more commonly affected and tend to develop more severe disease at younger ages than females, though the reason for this sex predilection is not fully understood.

Clinical Presentation

The clinical presentation of HCM ranges from complete absence of signs to acute cardiovascular emergency. Understanding this spectrum is important for owners and veterinarians alike.

Subclinical (Preclinical) HCM

Many cats with HCM are completely asymptomatic for months to years. The diagnosis is made incidentally during a routine health examination when the veterinarian detects a heart murmur or gallop rhythm (an extra heart sound reflecting abnormal ventricular filling), or during echocardiography performed for screening purposes in at-risk breeds. The natural history of subclinical HCM is variable — some cats remain stable for years, while others progress rapidly to congestive heart failure.

Congestive Heart Failure (CHF)

When compensatory mechanisms are overwhelmed, fluid accumulates — either within the lungs (pulmonary oedema) or in the pleural space around the lungs (pleural effusion). The cardinal sign is acute respiratory distress: open-mouth breathing, orthopnoeic posture (crouched with elbows out), rapid shallow breathing, and extreme reluctance to move. This is a veterinary emergency requiring immediate intervention.

Less acute presentations include increased resting respiratory rate, exercise intolerance (though this is difficult to assess in cats), decreased appetite, and weight loss.

Arterial Thromboembolism (ATE)

Left atrial enlargement creates conditions that promote thrombus formation. When a thrombus breaks free and lodges in a major artery — most commonly at the aortic trifurcation (‘saddle thrombus’), blocking blood flow to the hind limbs — the result is sudden, severe pain and acute hindlimb paralysis. Affected cats present with cold, painful hind limbs, absent femoral pulses, crying in distress, and cyanotic (blue-grey) nail beds. ATE carries a poor immediate prognosis, with reported mortality rates of 30 to 50% in the acute phase.

Warning Signs of Acute Cardiac Emergency Contact a veterinarian immediately if your cat shows: open-mouth breathing, rapid or laboured breathing at rest, sudden hind limb weakness or paralysis, blue or grey gums or tongue, or extreme distress. These are life-threatening emergencies.

Diagnosis

No single clinical finding is diagnostic for HCM. The diagnosis requires a systematic approach combining physical examination, screening biomarkers, and definitive imaging.

Cardiac Auscultation

Detection of a heart murmur, gallop rhythm, or arrhythmia during physical examination raises suspicion for cardiac disease but is neither sensitive nor specific for HCM. Approximately 50% of cats with HCM have no audible murmur (murmur-negative HCM), and murmurs in young cats are often innocent (physiological). Auscultation is a screening tool, not a diagnostic one.

NT-proBNP and Cardiac Troponin I

NT-proBNP (N-terminal pro-brain natriuretic peptide) is released by cardiac muscle cells under stretch and pressure. Elevated concentrations in blood or from an in-clinic SNAP test suggest cardiac remodelling and can help distinguish cardiac from non-cardiac causes of respiratory signs. Cardiac troponin I (cTnI) is a marker of myocardial injury. Both are useful screening and monitoring biomarkers but do not replace echocardiography for definitive diagnosis or staging.

Echocardiography: The Gold Standard

Transthoracic echocardiography performed by a cardiologist or experienced operator is the definitive diagnostic test for HCM. It allows direct measurement of left ventricular wall thickness (HCM is diagnosed when diastolic wall thickness exceeds 6 mm in the absence of other causes), assessment of left atrial size, evaluation of diastolic function, detection of dynamic left ventricular outflow tract obstruction (LVOTO), and identification of intracardiac thrombi.

Left atrial-to-aortic ratio (LA:Ao) is a particularly important prognostic parameter — a ratio above 1.5 to 1.6 indicates significant left atrial enlargement and substantially elevated risk of CHF and ATE.

Genetic Testing

DNA tests for the Maine Coon and Ragdoll MYBPC3 mutations are commercially available and are recommended for breeding animals of these breeds. A negative result does not exclude HCM — it only confirms absence of that specific known mutation. Cats from these breeds should still undergo regular echocardiographic screening regardless of genetic test results.

Treatment

There is currently no treatment proven to reverse HCM or prevent its progression in all cats. Management focuses on controlling clinical signs, preventing complications, and maintaining quality of life.

Preclinical HCM (No Signs, No LA Enlargement)

No treatment has been shown to delay progression from subclinical HCM to CHF in cats without left atrial enlargement. Regular monitoring — echocardiography every 6 to 12 months and NT-proBNP measurement — is the appropriate approach at this stage. Avoiding unnecessary stress and ensuring an optimal body condition are reasonable supportive measures.

Preclinical HCM with Left Atrial Enlargement

Cats with significant left atrial enlargement (LA:Ao > 1.5) are at elevated risk of CHF and ATE. The BLOOM trial demonstrated that clopidogrel (an antiplatelet agent) significantly reduces the risk of ATE in cats with left atrial enlargement compared to aspirin. Clopidogrel (18.75 mg per cat q24h) is now the standard of care for ATE prevention in this population. Some cardiologists also initiate diuretic therapy (furosemide) at this stage, though evidence supporting this in preclinical cats is limited.

Acute Congestive Heart Failure

• Furosemide (loop diuretic): The cornerstone of CHF management. Reduces fluid accumulation in the lungs and pleural space. Administered parenterally in the acute setting; oral maintenance dosing thereafter.
• Oxygen supplementation: Essential in the acute phase for cats in respiratory distress.
• Thoracocentesis: Pleural fluid removal by needle aspiration provides immediate relief in cats with pleural effusion — often producing dramatic improvement within minutes.
• Atenolol or diltiazem: Rate control agents used in cats with significant tachycardia or LVOTO. Choice depends on specific haemodynamic profile.
• ACE inhibitors (e.g., benazepril, enalapril): Commonly used but evidence in cats is mixed. May be of benefit in cats with concurrent systemic hypertension or significant mitral regurgitation.

Monitoring at Home

Owners of cats with HCM are taught to monitor resting respiratory rate (RRR) at home — typically by counting breaths per minute while the cat is sleeping. A rate consistently above 30 breaths per minute is a recognised trigger for veterinary contact. Several free smartphone apps facilitate RRR tracking over time, enabling trend detection. The resting respiratory rate is the single most practical and sensitive early warning sign of developing pulmonary oedema available to owners.

Stage	Characteristics	Typical Management
A (At-risk)	Breed predisposition; no structural disease detected	Genetic testing; annual echo screening
B1 (Subclinical, mild)	Structural changes; no LA enlargement; no signs	6–12 monthly echo; no pharmacotherapy indicated
B2 (Subclinical, significant)	LA enlargement (LA:Ao >1.5); no signs	Clopidogrel; consider furosemide; 3–6 monthly monitoring
C (CHF)	Clinical signs of heart failure present	Furosemide; clopidogrel; rate control; oxygen; thoracocentesis if needed
D (Refractory CHF)	CHF not controlled on standard therapy	Combination diuretics; specialist referral; palliative care discussion

Prognosis

The prognosis for HCM is highly variable and depends primarily on disease stage at diagnosis, left atrial size, and the presence or absence of complications. Cats with subclinical HCM and no left atrial enlargement may remain stable for years. Median survival after first episode of CHF is reported at approximately 563 days in some studies, though this varies widely. Survival after ATE is considerably shorter — median survival times of 2 to 6 months are reported, with many cats not surviving the acute event.

Quality of life is generally maintained well in cats with mild to moderate disease on appropriate therapy, and many owners of cats with HCM report satisfactory periods of stability and normal cat behaviour between acute episodes.

Key Takeaways

• HCM is the most common feline heart disease and is often completely silent until a serious complication occurs
• Breeds at highest risk include Maine Coon and Ragdoll; genetic testing is available but does not exclude HCM if negative
• Echocardiography is the gold standard for diagnosis and staging — auscultation alone is insufficient
• Resting respiratory rate monitoring at home is the single most useful tool for early detection of decompensation
• Clopidogrel is standard of care for ATE prevention in cats with left atrial enlargement
• Acute open-mouth breathing, respiratory distress, or sudden hind limb paralysis are emergencies — seek immediate veterinary care

References

1. Côté E et al. (2011). Feline hypertrophic cardiomyopathy: an update. J Vet Cardiol 13(1):5–17.

2. Payne JR et al. (2010). Prognostic indicators in cats with hypertrophic cardiomyopathy. J Vet Intern Med 24(3):495–505.

3. Hogan DF et al. (2015). Secondary prevention of cardiogenic arterial thromboembolism in the cat: The double-blind, randomized, positive-controlled feline arterial thromboembolism; clopidogrel vs. aspirin trial (FAT CAT). J Vet Cardiol 17 Suppl 1:S306–17.

4. Meurs KM et al. (2005). A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathy. Hum Mol Genet 14(23):3587–93.

5. Fox PR et al. (2018). Multicenter evaluation of plasma N-terminal probrain natriuretic peptide to detect cardiomyopathy in asymptomatic cats. J Vet Intern Med 32(1):41–52.

6. Luis Fuentes V et al. (2020). ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats. J Vet Intern Med 34(3):1062–77.